Реферат
Relato de caso de paciente de 38 anos, feminina, com lúpus eritematoso sistêmico (LES) que apresentou evento tromboembólico arterial agudo em membro inferior direito. A investigação evidenciou a presença de anticorpos antifosfolípides e vegetação asséptica em válvula mitral, endocardite de Libman-Sacks (eLS). São discutidas as possíveis causas de eventos tromboembólicos arteriais no LES, com ênfase nas recomendações atuais para diagnóstico e tratamento da eLS.
Case report of a 38-year-old female patient with systemic lupus erythematosus (SLE) who presented an acute arterial thromboembolic event in the right lower limb. Investigation showed the presence of antiphospholipid antibodies and sterile vegetation in the mitral valve, Libman-Sacks endocarditis (LSE). Possible causes of thromboembolic events in SLE are discussed, with emphasis on current recommendations for diagnosis and treatment of LSE.
Тема - темы
Adult , Female , Humans , Antibodies, Antiphospholipid/immunology , Endocarditis/etiology , Endocarditis/immunology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Thrombosis/etiology , Thrombosis/immunologyРеферат
Se presenta el caso de una mujer joven, sin antecedentes de importancia, que muestra trombosis de grandes y pequeños vasos. A pesar del tratamiento con anticoagulación y corticoides en dosis altas, desarrolla necrosis cutánea y una importante respuesta inflamatoria sistémica con disfunción orgánica múltiple, por lo que .se le indicó plasmaféresis y, posteriormente, rituximab, con buena respuesta. Se discute el síndrome antifosfolípidos con énfasis en los anticuerpos antiprotrombina y la patogenia de la microangiopatía en el síndrome antifosfolípidos catastróficos.
We present the case of a young, otherwise healthy woman, who developed thrombosis of large and small vessels and capillaries. Despite anticoagulation treatment and high doses of glucocorticoids, she developed cutaneous necrosis and systemic inflammatory response with multiple organ dysfunction. Plasmapheresis and rituximab were administered with good response. We discuss the antiphospholipid syndrome, with emphasis on antiprothrombin antibodies and the pathogenesis of microangiopathy in antiphospholipid syndrome.
Тема - темы
Humans , Female , Adult , Vascular Diseases/complications , Vascular Diseases/immunology , Vascular Diseases/therapy , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/immunology , Antiphospholipid Syndrome/therapy , Antibodies/immunology , Catastrophic Illness , Prothrombin/immunology , Thrombosis/complications , Thrombosis/immunology , Thrombosis/therapyРеферат
El síndrome antifosfolípido (SAF) es una enfermedad autoinmune sistémica que se caracteriza por la presencia de fenómenos trombóticos y/o morbilidad durante el embarazo, asociado a la producción de autoanticuerpos dirigidos contra proteínas que reconocen fosfolípidos aniónicos o contra el complejo fosfolípido/proteína denominados anticuerpos antifosfolípidos (aPL). Dichos anticuerpos serían marcadores de enfermedad y además tendrían una relación directa en la génesis de ésta. El conocimiento respecto al origen de dichos anticuerpos, sus especificidades antigénicas y su rol en la inmunopatogenia del SAF son puntos importantes que son motivo actual de investigación y que permitirán a futuro el desarrollo de nuevas armas terapéuticas.
The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the presence of thrombotic and /or morbid phenomena during pregnancy, associated to the production of autoantibodies directed against proteins that recognize anionic phospholipids, or against the phospholipid/protein complex known as antiphospholipid antibodies. Said antibodies seem to be disease markers and would have a direct relation in its genesis. Knowledge with respect to the origin of said antibodies, antigenic specificities and its role in APS immunopathogenesis are important points that are currently being investigated and will give way to the future development of new therapeutic instruments.
Тема - темы
Humans , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/immunology , Thrombosis/immunologyРеферат
OBJECTIVES: To describe the clinical outcomes and thrombotic events in a series of critically ill cancer patients positive for antiphospholipid (aPL) antibodies. DESIGN: Retrospective case series study. SETTING: Medical-surgical oncologic intensive care unit (ICU). PATIENTS AND PARTICIPANTS: Eighteen patients with SIRS/sepsis and multiple organ failure (MOF) and positive for aPL antibodies, included over a 10-month period. INTERVENTIONS: None MEASUREMENTS AND RESULTS: aPL antibodies and coagulation parameters were measured up to 48 hours after the occurrence of acrocyanosis or arterial/venous thrombotic events. When current criteria for the diagnosis of aPL syndrome were applied, 16 patients met the criteria for "probable" and two patients had a definite diagnosis of APL syndrome in its catastrophic form (CAPS). Acrocyanosis, arterial events and venous thrombosis were present in eighteen, nine and five patients, respectively. Sepsis, cancer and major surgery were the main precipitating factors. All patients developed MOF during the ICU stay, with a hospital mortality rate of 72 percent (13/18). Five patients were discharged from the hospital. There were three survivors at 90 days of follow-up. New measurements of lupus anticoagulant (LAC) antibodies were performed in these three survivors and one patient still tested positive for these antibodies. CONCLUSIONS: In this small series of patients, we observed a high frequency of auto-antibodies and micro- and macro-vascular thrombotic events in critically ill cancer patients. The coexistence of sepsis or SIRS and aPL antibodies was often associated with MOF and death. More studies are necessary to determine the pathophysiological significance of antiphospholipid antibodies in severely ill cancer patients.
Тема - темы
Aged , Female , Humans , Male , Middle Aged , Antibodies, Antiphospholipid/blood , Critical Illness , Gastrointestinal Neoplasms/complications , Lymphoma, Non-Hodgkin/complications , Multiple Organ Failure/etiology , Sepsis/complications , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/immunology , Gastrointestinal Neoplasms/immunology , Laryngeal Neoplasms/complications , Laryngeal Neoplasms/immunology , Lymphoma, Non-Hodgkin/immunology , Multiple Organ Failure/immunology , Retrospective Studies , Sepsis/immunology , Systemic Inflammatory Response Syndrome/etiology , Systemic Inflammatory Response Syndrome/immunology , Thrombosis/complications , Thrombosis/immunologyРеферат
El Síndrome antifosfolípido (SAF) es una trombofilia adquirida, que se caracteriza por presentar eventos trombóticos recurrentes y complicaciones obstétricas en presencia de anticuerpos antifosfolípidos (aFL), los cuales son pesquisados por pruebas de laboratorio como anticoagulante lúpico y anticuerpos anticardiolipina. En esta revisión se muestran los aspectos más relevantes del SAF, destacando los avances en fisiopatología y criterios diagnósticos.
Тема - темы
Humans , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/physiopathology , Antiphospholipid Syndrome/immunology , Thrombosis/immunology , Complement Activation/immunology , Antibodies, Anticardiolipin/blood , Antibodies, Antiphospholipid/immunology , Pregnancy Complications/immunology , Endothelial Cells/immunology , Lupus Coagulation Inhibitor/blood , Antiphospholipid Syndrome/complications , Thrombosis/therapyРеферат
ABSTRACT Introduction. We investigated the activated protein C resistance (APCR) phenotype and the lupus anticoagulant (LA), activity induced by anti-β2-glycoprotein-I (anti-β2GP-I) antibodies. Patients and methods. We studied plasma and sera samples from 29 patients with persistently positive anti-β2GP-I: 22 with thrombosis (12 with primary APS, 10 with APS secondary to SLE) and seven without thrombosis (all with SLE); 25 healthy subjects were studied as controls. We detected anticardiolipin antibodies (ACA); IgG (and its subclasses) and IgM anti-β2GP-I, on irradiated and non-irradiated plates by ELISA. APCR was assessed by the activated partial thromboplastin time (APTT)-based assay and by the modified test. The FV Leiden mutation was studied by PCR. LA determination included screening and confirmatory dRVVT. Serum anti-β2GP-I were affinity purified on sepharose columns and their isotype, subclass, and reactivity against various antigens were studied by ELISA. Results. We found that titers of IgG anti-β2GP-I on irradiated plates were higher than on non-irradiated plates (p = 0.002), IgG2 was the predominant subclass. Fifteen patients (13 with thrombosis) had LA and 15 (also 13 with thrombosis) induced the APCR phenotype. Eleven (all with thrombosis) had both. Two patients were heterozygous for the Leiden mutation. Two purified antibodies, monospecific for β2GP-I, induced an in vitro APCR phenotype and LA activity. Conclusions. Our results seem to indicate that the inhibition of the APC anticoagulant function by IgG2 anti-β2GP-I with LA activity may be one of the responsible mechanisms of thrombophilia in patients with APS.
Introducción. Investigamos la resistencia a la proteína C activada (RPCA) y la actividad de anticoagulante lápico (AL), inducidas por anticuerpos anti-β2-glicoproteína-I (anti-β2GP-I). Pacientes y métodos. Estudiamos los plasmas y sueros persistentemente positivos para anti-β2GP-I de 29 pacientes: 22 tuvieron trombosis (12 con síndrome de antifosfolípidos (SAF) primario y 10 con SAF secundario a lupus erítematoso generalizado (LEG)) y siete sin trombosis (todos con LEG). Como controles estudiamos 25 sueros de personas clínicamente sanas. Detectamos anticuerpos anticardiolipina, anti-β2GP-I IgG (y sus subclases) e IgM por ELISA en placas irradiadas y no irradiadas. Evaluamos la RPCA por medio del tiempo parcial de tromboplastina activada y por la prueba modificada. Estudiamos la mutación FV de Leiden por PCR y el anticoagulante lápico con el método de dRVVT screening y confirmatorio. Después de purificar los anti-β2GP-I séricos con una columna de antígeno unido a sefarosa, analizamos por ELISA sus isotipos, subclases y reactividad contra β2GP-I y algunos fosfolípidos. Resultados. Los títulos de anti-β2GP-I IgG fueron más altos en placas irradiadas que en no irradiadas (p = 0.002), predominó la subclase IgG2. Quince plasmas (13 de pacientes con trombosis) tuvieron AL y 15 (13 también de pacientes con trombosis) indujeron el fenotipo de RPCA. Once plasmas (todos de pacientes con trombosis) indujeron ambas actividades. Dos pacientes fueron heterocigotos para la mutación de Leiden. Dos anticuerpos purificados monoespecíficos para β2GP-I indujeron el fenotipo de la RPCA y la actividad de AL in vitro. Conclusiones. Nuestros resultados sugieren que la RPCA, inducida por los anti-β2GP-I que concomitantemente tienen actividad de AL, puede tener implicaciones patogénicas en la trombofílía del SAF.
Тема - темы
Adult , Aged , Female , Humans , Male , Middle Aged , Activated Protein C Resistance/immunology , Autoantibodies/immunology , Glycoproteins/immunology , Immunoglobulin G/pharmacology , Lupus Coagulation Inhibitor/blood , Thrombophilia/immunology , Thrombosis/etiology , Antibody Specificity , Activated Protein C Resistance/etiology , Antibodies, Anticardiolipin/blood , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/immunology , Autoantibodies/isolation & purification , Autoantigens/immunology , Autoimmune Diseases/blood , Autoimmune Diseases/immunology , Enzyme-Linked Immunosorbent Assay , Factor V/analysis , Factor V/genetics , Immunoglobulin G/immunology , Immunoglobulin G/isolation & purification , Immunoglobulin M/pharmacology , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Partial Thromboplastin Time , Phenotype , Plasma , Prothrombin Time , Plastics/radiation effects , Thrombophilia/blood , Thrombophilia/etiology , Thrombophilia/genetics , Thrombosis/blood , Thrombosis/genetics , Thrombosis/immunologyРеферат
Background: Antiphospholipid antibodies have been found in the sera from patients with idiopathic and secondary glomerulopathies, mainly related to lupus. No special attention has been devoted to idiopathic membranous nephropathy, a glomerular disease with a high frequency of thrombotic complications, particularly of the renal vein. Aim: To study the presence and significance of antiphospholipid antibodies in idiopathic membranous nephropathy. Material and methods: Anticardiolipin and anti-ß2-glycoprotein-I IgG antibodies were measured in serum samples from 21 patients with idiopathic membranous nephropathy (age range 11-75 years, 5 female). The medical records of 20 of these patients were reviewed, looking for vascular complications and nephrological evolution during a follow-up period that ranged from two to 277 months. Results: Five patients had anticardiolipin antibody titers over the cutoff for normal values, and two others were positive for anti-ß2-glycoprotein-I, without cross-reactivity. There was no difference in the incidence of thrombotic complications in the renal vein, or other locations, between these seven patients and the remaining patients. No differences in the clinical course of the nephropathy were detected either. Conclusions: Antiphospholipid antibodies may be found in patients with primary membranous nephropathy. They are not related to thrombosis or a worse evolution.
Тема - темы
Adolescent , Adult , Male , Humans , Female , Child , Middle Aged , Antibodies, Anticardiolipin/blood , Glomerulonephritis, Membranous/complications , Glomerulonephritis, Membranous/immunology , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/immunology , Thrombosis/diagnosis , Thrombosis/immunologyРеферат
Antiphospholipid antibodies (APA) have aroused multispeciality interests. In our study of 200 cases worked up for APA, we have used a few simple coagulation tests to detect lupus anticoagulant (LA) and ELISA to detect anticardiolipin antibodies. The positivity rate for LA among cases with recurrent pregnancy loss was 4.16% and for aCL 20.8%. The positivity rate for LA in patients with venous thrombosis was 6.2%, in arterial thrombosis was 7.14% and in SLE patients was 58.3%. In conclusion APAs are to be looked for in cases of recurrent pregnancy loss, thrombosis in people < 45 years of age without risk factors and SLE patients to assess the thrombotic risk and to decide on anti coagulant therapy for further management.
Тема - темы
Abortion, Habitual/immunology , Adult , Antibodies, Anticardiolipin/blood , Antibodies, Antiphospholipid/blood , Female , Humans , Lupus Coagulation Inhibitor/blood , Lupus Erythematosus, Systemic/immunology , Male , Middle Aged , Pre-Eclampsia/immunology , Pregnancy , Thrombosis/immunologyРеферат
The antiphospholipid syndrome encompasses a wide spectrum of presentations cutting across all subspecialties of medicine. It is characterized by recurrent thrombotic events involving both the arterial and venous systems. Large arteries and veins as well as the microcirculation are involved. Recurrent strokes, myocardial infarction, pulmonary embolism, gangrene of the digits, etc. cause much morbidity and mortality in affected patients. It is recognized as an important cause of recurrent pregnancy loss. The risk in pregnancy extends to a propensity towards pre-eclampsia, abruptio placentae and intrauterine growth retardation. It often manifests as asymptomatic thrombocytopenia and sometimes as a life-threatening form called catastrophic anti-phospholipid syndrome. The management of thrombotic events rests on high grade anticoagulation (INR 3-4) as lower values of INR than this often fail to prevent recurrence. Aspirin is generally added in case of arterial thrombosis. A combination of heparin and aspirin at least in the first trimester and sometimes throughout pregnancy is used to prevent foetal loss.
Тема - темы
Abortion, Habitual/immunology , Antiphospholipid Syndrome/diagnosis , Female , Humans , Pregnancy , Pregnancy Complications/drug therapy , Thrombosis/immunologyРеферат
Since heparin is an anticoagulant commonly used in hemodialysis and the patients on hemodialysis are repeatedly exposed to heparin, heparin may be the cause of the development of heparin-dependent antibodies and thrombotic complications in patients on hemodialysis. The purpose of this study was to determine the prevalence and the clinical significance of the antibodies against heparin-platelet factor 4 complexes as determined by enzyme immunoassay in patients on maintenance hemodialysis. The prevalence of anti-heparin-platelet factor 4 antibodies was higher in hemodialysis patients than in normal subjects (8.8 vs 0.0%, p<0.05). The number of past episodes of vascular access obstruction per year was significantly higher in the anti-heparin-platelet factor 4 antibody positive group than antibody negative group. Anti-heparin-platelet factor 4 antibody positive patients experienced more frequent vascular access obstructions than control subjects. In conclusion, anti-heparin-platelet factor 4 antibody might be a risk factor for vascular access obstructions in patients with end-stage renal disease on maintenance hemodialysis.
Тема - темы
Adult , Female , Humans , Male , Middle Aged , Autoantibodies/immunology , Autoimmune Diseases/immunology , Catheters, Indwelling , Enzyme-Linked Immunosorbent Assay , Heparin/immunology , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/therapy , Platelet Factor 4/immunology , Recurrence , Renal Dialysis , Risk Factors , Thrombophilia/immunology , Thrombosis/epidemiology , Thrombosis/immunology , Thrombosis/prevention & controlРеферат
Los anticuerpos antifosfolípidos (AAP) son un grupo de autoanticuerpos con afinidades variables por complejos de proteínas y fosfolípidos. Los anticuerpos anticardiolipina (ACAs) son detectados usualmente por técnicas de ELISA, mientras que el anticoagulante lúpico es medido como una actividad que prolonga las reacciones de la coagulación dependientes de fosfolípidos. Se han descrito en enfermedades autoinmunes, infecciosas, asociados a drogas, en neoplasias y en individuos sanos y se han asociado con fenómenos trombóticos venosos y arteriales, abortos a repetición y trombocitopenia, constituyendo lo que se denomina "síndrome antifosfolípido" (SAF)
Тема - темы
Abortion, Habitual/immunology , Antibodies, Anticardiolipin/immunology , Antibodies, Antiphospholipid/immunology , Lupus Coagulation Inhibitor/immunology , Antiphospholipid Syndrome/immunology , Thrombosis/immunologyРеферат
A síndrome de anticorpos antifosfolipídios é um distúrbio adquirido das proteínas sangüíneas associadas aos quadros trombóticos, aborto de repetição e trombocitopenia. Uma série de manifestações clínicas diversas tem sido associadas a estes anticorpos e o presente estudo descreve os achados observados no hospital de Base no período de 1993 a 1995 em 123 pacientes com positividade para estes anticorpos do quais em 82 constatou-se um quadro trombótico em 18, abortos de repetição, e em 23 manifestações diversas como no lúpus eritematoso sistêmico, cardiopatias, livedo reticular, tireoidite de Hashimoto, doença de Takayassu e outras. Os anticorpos antifosfolipídios representam uma freqüente condição trombogênica merecendo uma investigação mais sistemática nos quadros trombóticos e de abortos de repetição onde uma causa aparente não é detectada.